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Abstract  
Background: Drop-out is an important problem in the treatment of substance use disorder. The focus 
of this study was to investigate the effectiveness of within treatment assessment with feedback directly 
to patients with multiple substance use disorder on outpatient individual treatment adherence. 
Feedback consisted of personal resources’ and readiness to change status and progress that facilitate 
or hinder change, thereby using graphical representation. 
 
Methods: Informed consent was obtained from both the control and experimental groups to be 
involved in research and follow-up. Following Zelen’s single consent design, baseline participants 
(n=280) were randomised (sample-size-estimation:80%power,p=.05,2-sided) and treatment consent 
was obtained from those allocated to the experiment (n=142). In both groups, equal numbers of 
patients did not attend sessions after allocation. So, 227 persons were analyzed according to 
intention-to-treat analysis (ITT:experiment n=116;control n=111). Excluding refusals 211 participants 
remained for per-protocol analysis (PP:experiment n=100;control n=111),  
The study was conducted in five outpatient treatment-centres of a large network (De Sleutel) in 
Belgium. Participants were people with multiple substance use disorder –abuse and dependence- who 
had asked for treatment and who had been advised to start individual treatment after a standardised 
admission assessment with the European Addiction Severity Index.  
The experimental condition consisted of informing the patient about the intervention and of 
subsequent assessments plus feedback following a protocol within the first seven sessions. 
Assessments were made with the Readiness to Change Questionnaire and the Personal Resources 
Diagnostic System. The control group received the usual treatment without within treatment 
assessment with feedback. The most important outcome measure in this analysis of the study was the 
level of adherence to treatment at and beyond eight sessions.  
 
Results: Individual treatment that included assessment with feedback increased adherence to 
treatment at and beyond eight sessions (RR=1.6,95%CI:1.2-2.2). Benefit was also found at and 
beyond twelve sessions, which was the number of sessions required to complete 90% of the 
assessments with feedback in practice (RR=1.6,95%CI:1.2-2.5). 
 
Conclusions: Assessment with feedback in routine practice improved adherence to treatment. More 
research is needed to evaluate progress in social functioning and motivation to change in outpatient 
treatment of substance use disorder, thereby using objective measures 
 
Trial registration: Current Controlled Trials ISRCTN65456186 
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BACKGROUND  
Drop-out is an important problem in the treatment of people with multiple substance 
use disorder. There is growing agreement for substance abuse and dependence, being a 
chronic and relapsing condition [1-3]. The effectiveness of treatment to stabilize or overcome 
a chronic condition is strongly related to treatment compliance [3]. Among alcohol-dependent 
people, diabetics or persons with hypertension it is common to find a compliance rate below 
50% [4].  
In a therapeutic community environment for drug addicted people, evidence has been 
found that family-[5, 6], social network- [7, 8], and staff-involvement [9] [10], improve 
retention levels.  In the broader area of health care, patient-based measures in routine practice 
combined with feedback were found to improve significantly the process and outcome of 
patient care [11]. In mental healthcare, feedback to clinicians about patients’ progress based 
on routine outcome monitoring affected outcome and even the number of sessions in 
psychological interventions [12, 13].  
In the realm of outpatient treatment of substance use disorder, compliance is also 
associated with session attendance a/o adherence to treatment. Regular treatment often relies 
on assessment, but outside its use in planning, monitoring, and evaluating interventions, 
assessment and feedback as part of the treatment itself and its positive effect on patient 
adherence is under–investigated. Kypri et al. focused on this issue, related to contamination of 
clinical trials [14], and found that routine screening and minimal assessment themselves may 
produce some benefit [15]. In line with the studies based on routine outcome monitoring in 
psychotherapy [12, 16], Hawkins et al. [17] developed a similar approach in the treatment of 
substance use disorder. Their focus was on feedback to clinicians about lack of progress in 
order to reduce the risk of patient drop-out.  
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In this study, assessment and feedback is introduced as part of the treatment process 
itself. It is aimed to offer opportunities to support counselling by establishing a collaborative 
relationship and a patient-centred focus [18, 19]. This therapeutic method of assessment [20] 
seeks to integrate key features of therapeutic alliance between clinician and patient in 
assessment and feedback sessions. Feedback is given to the patient each time at the next 
session after assessment. It consists of communicating the status of substance use, readiness 
to change, and personal resources that may facilitate or hinder change. Repeated assessment 
and graphical representation is considered to provide opportunities for feeding back of 
progress, treatment recommendation, and further action. It is also providing the patient with 
new ways of thinking and feelings about self and others. 
This study addresses the question whether continuing rounds of assessment with 
personal feedback to patients that replace a number of regular outpatient sessions in the 
treatment of people with multiple substance use disorder, improves adherence, compared to 
an outpatient approach without such within treatment assessment and feedback. It is the most 
important aim of this study to investigate the effectiveness of within treatment assessment and 
personal feedback to patients on outpatients’ adherence to treatment. The reporting follows 
the CONSORT-guidelines [21-23]. 
 
METHOD 
Study Design 
In an attempt to determine whether enhanced adherence could be demonstrated by the 
introduction of within treatment assessment and personal feedback in outpatient treatment of 
substance use disorder, we set up an experimental study. This study was a multi-centre 
randomised controlled trial registered in the ISRCTN-database (ISRCTN65456186). It was 
embedded within an already existing system to ask informed consent to all patients for the use 
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of admission assessment and treatment data for research purposes, and for follow-up. To 
minimize problems associated with the clinicians’ resistance  to enter patients into a clinical 
trial, Zelen’s single consent design was chosen [24-26]. The key characteristic of this method 
is that participants were randomised and treatment consent was obtained from participants 
who were allocated to the experimental intervention, while controls did not receive the 
experimental treatment but get the best usual care. In such an open trial, statistical power can 
be affected by a high proportion of participants getting usual care. Therefore, Adamson et al. 
[27] advised performing sample-size-estimation before the start of the project and an 
intention–to-treat analysis.  
 
Setting and Participants 
All persons who entered one of the five outpatient drug-treatment centres of the 
treatment network ‘De Sleutel’ in Belgium between March 2007 and March 2009 were 
candidates for inclusion in the study. Based upon yearly reports, patient characteristics in the 
five centres were assumed to be very comparable. To be taken in charge for treatment in one 
of these centres, patients should be diagnosed DSM IV substance abuse or dependence for at 
least one substance, exclusive single alcohol abuse or dependence. The inclusion criteria for 
the trial were that the patient: (1) gave informed consent about the use of data and being 
contacted for follow-up,  (2) sufficiently understood the Dutch language, (3) passed the full 
admission assessment, consisting of at least a first contact session, the EuropASI-interview 
and a feedback session, and (4) was advised to start individual treatment. The study was 
approved by the Central Ethics Board for the Mental Health Sector of the n.p.o. Provincialat 
of the Brothers of Charity (ref. OG054-2006-19). 
 
Assessment instruments 
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EuropASI and feedback form 
Admission assessment was based upon the European version of the Addiction Severity 
Index (EuropASI)[28]. The Dutch version of EuropASI (Cronbach’s alphas >=.70, except for 
employment status) [29], adapted for Flanders, was used. This semi-structured interview 
offers an inventory of problems in seven potential problem areas (physical health, education-
work-income, alcohol use, drug use, judicial, relations, psycho-emotional). The information 
from ASI is synthesized on a two-sided feedback form, placing positive aspects of the 
patient’s experience against the problems in each life area. The feedback form helps clinicians 
to communicate findings from EuropASI with the patient and to suggest and support 
treatment options [30]. 
 
Readiness to Change Questionnaire (RCQ) 
The RCQ was used for within treatment assessment and feedback. Originally, the 
RCQ was a self-rating questionnaire [31] used to assess the first three stages of change, which 
are pre-contemplation, contemplation and action. The Dutch version of this instrument [32] 
has been adapted for poly-drug abusers. For each substance separately, being in action could 
be distinguished from not being in action (Cronbach’s alphas >= .70, except for pre-
contemplation) [33]. Feedback was based on the principles from the trans-theoretic model 
approach. For each substance that was used in the last 30 days, the clinician commented on 
whether the person was in pre-, contemplation or in action. The information about stage of 
change was further elaborated, making use of the number and type of used substances, and the 
number of use-days. 
 
Personal Resources Diagnostic system (PREDI) 
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Two scales were used within treatment from PREDI [34], originally a German 
instrument consisting of three scales: personal resources and wish to change. The personal 
resources scale provided the appreciation of both the clinician and the patient, the wish to 
change scale only the patient’s appreciation in 16 important life-areas, which were: every day 
life situation, living situation, financial situation, legal situation, work situation, health status, 
health behaviour, substance use, self-esteem, self-realization, self-control, contact with reality, 
partner relation, family relations, social relations, social cultural situation. It was translated 
into Dutch, using common rules for cross-cultural adaptations of health measurements [35]. 
Preliminary to this study, the system was validated in a small sample of patients with 
substance use disorder (personal resources’ Cronbach’s alpha=.81; wish to change’s 
Cronbach’s alpha=.83)[36]. Feedback consisted of the synthesis of a patient’s particular 
personal resources and a focus on the life areas where the person clearly indicated a wish to 
change.  
  
Study interventions 
The trial was presented in the centres during the first quarter of 2007. Clinicians were 
mainly social, educational, and/or psychological workers or psycho-therapists. Their basic 
training was completed with EuropASI-assessment and feedback, and with motivational 
interviewing. They had at least one year of training or experience. Inspired by Del Boca & 
Darkes’ guidelines [37] for enhancing validity and utility of randomised controlled trials, a 
manual was devised that included a training DVD for the experimental sessions. Extra 
training for supplementary assessment (RCQ and PREDI) with feedback took place in the 
centres between April and June 2007.  
The admission assessment was similar in all centres for all patients. This study focused 
on the individual treatment after admission, where the treatment length usually was open-
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ended. Regular treatment consisted of non-manualized individual counselling sessions of 
about one hour, principally aimed at changes in drug-use behaviour. The expected treatment 
duration, number or intensity of counselling sessions were defined only by the clinicians’ 
subjective judgment about progress towards goals and life changes, although such progress 
was not measured objectively. 
   
In the experiment, continued assessment and feedback sessions according to the 
manual, replaced the regular treatment sessions (Table 1). The therapists themselves 
administered the assessments and/or gave feedback within the one-hour-sessions instead. 
 
Unlike those in the control group, people in the experimental group were informed in 
the first session about further sessions dealing with continued assessment and feedback and 
asked for consent. During session three (Table 1), the clinician provided the patient with 
feedback on RCQ using the trans-theoretic model, graphical representation of change and 
worksheets [38]. For feedback on PREDI a standardised form was used that showed a time-
schedule and the personal resources on which to focus further actions. Planning for repeated 
measurement with feedback using the same instruments was left to the clinicians, with about 
30 days in between as a guideline. The researcher closely followed up the clinicians’ 
adherence to the manual. 
 
Outcome measure 
Data-collection on patients’ attendance at counselling sessions was part of the routine-
administration in the central database of the De Sleutel-network. The start and end date as 
well as the clinicians’ evaluation at the end of the whole treatment was also documented, but 
the most important outcome measure in this study was the adherence to individual counselling 
treatment. Adherence was measured by counting the total number of sessions between the 
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date of the first session after admission and the last session date. Therefore, the initial 
assessment sessions being part of the admission assessment did not count towards sessions in 
the outcome measure. Since the first five trial related assessment and feedback sessions in the 
experimental group take approximately seven sessions (Table 1), completing at least eight 
individual counselling sessions after admission was set as a first outcome measure. In reality, 
however, 90% of the assessment and feedback activities took place within the first twelve 
sessions, so completion of at least twelve sessions was set as a second outcome measure. 
 
Sample size and power 
Sample size estimation was based upon the results of a study on retention in treatment, 
retrieved from the central database of the De Sleutel-network during the period from 1999 to 
2006. The usual course of treatment took six months for 80% of the patients during that 
period, with a mean of 5.9 sessions (± 3.5). 56% of patients had fewer than five sessions, 
18.3% had eight or more sessions. Based upon 80% power to detect statistically significant 
differences (p=.05;two-sided), a sample size of at least 100 patients in each study arm was 
required to demonstrate doubling of the number of patients attending eight or more sessions. 
While power calculations yield the number of subjects needed at the end of follow-up, we 
aimed at selecting more subjects (n=320) and accounted for likely drop-out [39] (Figure 1).  
 
Randomisation and enrolment 
The researcher distributed five closed envelopes to each outpatient centre each month - 
two experimental/three controls or three experimental/two controls. Each of the closed 
envelopes was assigned to an eligible patient by the clinical supervisor, and only after the 
assignment was made the envelope was opened to determine whether the patient was assigned 
to the control group or the experimental group. The researcher evaluated monthly the 
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enrolment process and confirmed whether the patients assigned met or did not meet all 
eligibility criteria.  
 
320 patients were assessed for eligibility, of which 40 were excluded because they did 
not meet the inclusion criteria, so at baseline 280 persons were randomly assigned to the 
experimental group (n=142) and to the control group (n=138) (Figure1). 26 eligible patients 
assigned to the experimental group and 27 patients assigned to the control group and being 
referred to individual treatment did not attend any sessions after admission assessment. They 
were excluded from further analyses. Thus, the intention-to-treat analysis is based on 116 
patients in the experimental group and 111 patients in the control group. Of them who 
attended their first individual counselling session, 16 patients in the experimental group 
refused participation and were excluded for per-protocol analysis.  
 
Statistical Analysis 
The Pearson Chi-square test and the independent samples T-test were used to test for 
differences in patient characteristics between both allocations at baseline. A p-value of .05 or 
less was considered to indicate statistical significance. The outcome measure was adherence 
to treatment at and beyond eight and twelve sessions. Risk-ratios (RR) with accompanying 
95% confidence intervals were calculated to evaluate adherence to the individual treatment 
that included psychological assessment and feedback. In this study, the word “risk” referred to 
a desired effect. Risk ratios of 1 indicate a null-finding, while 95% confidence intervals (CI) 
should not include 1 to be statistically significant. Risk ratios >1 are indicating enhanced 
likelihood of the desired effect. All analyses were performed using SPSS for Windows 
(release 16.0).  
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RESULTS 
Baseline characteristics by allocation 
To exclude for bias, the characteristics at baseline of patients allocated to the 
experimental group are compared with those of the control group (Figure 1, first split). Table 
2 shows several patient characteristics in both groups. All data were retrieved from EuropASI. 
No statistically significant differences were found between the groups (p<.05), except for 
problem-severity concerning work and substance-abuse. In the control group, more patients 
had severity indexes for work above four and a bit smaller average substance-abuse severity 
index than the experimental group. The profiles showed that participants were mainly never-
married male Belgians with an average age of 27. Most patients lived with parents or alone. 
Their schooling degree was low with less than 10% who finished secondary school. About 
two-thirds were employed full-time or part-time. Cannabis was the primary substance of 
abuse, followed by cocaine, opiates, and amphetamines. For almost half of the study group, 
the treatment was their first treatment for drugs/substance abuse. Higher problem severity was 
most frequent in the area of drug abuse, followed by family and social relationships and 
psycho-emotional issues. No statistically significant difference between the two groups was 
found in the number of persons that did not present anymore after allocation (Figure1). These 
individuals – respectively 27 and 26 persons in the control and the experimental group – were 
not included in further analyses. 
 
Adherence to treatment 
The primary outcome measure for this study was treatment adherence at and beyond 
eight sessions. The results confirmed enhanced likelihood of this desired effect in patients 
allocated to the experimental condition. 
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Table 3 showed that adherence to treatment at and beyond eight sessions improved 
statistically significant in individual treatment where assessment and feedback was given 
(RR=1.6,95%CI:1.2-2.1 in intention-to-treat (n=227) or RR=1.6,95%CI:1.2-2.2 in per-
protocol (n=211)). It means that 60% more persons adhered to individual treatment for at least 
eight sessions if continued assessment and feedback was provided within the individual 
treatment sessions, compared to those who received regular sessions. This result was found in 
both intention-to-treat and per-protocol analysis.  
A second outcome measure was also set for adherence to treatment at and beyond 
twelve sessions. Yet, 90% of the assessment and feedback sessions (Table 1) took place 
within the first twelve sessions. In intention-to-treat analysis, the results showed again 
statistically significant improved adherence at and beyond twelve sessions, where continued 
assessment and feedback took place (RR=1.6,95%CI:1.0-2.5,n=227). In per-protocol analysis, 
the results even showed 70% more persons that adhered to individual treatment for at least 
twelve sessions (RR=1.7,95%CI:1.1-2.7,n=211). 
 
DISCUSSION 
Adherence in addiction treatment and studies is an important issue[40]. The results 
indicate that counselling sessions which included assessment with feedback directly to 
patients increased adherence to outpatient session-based treatment of substance use disorder, 
compared to an approach without assessment with feedback. Our results can be compared 
with findings in general health care [11] and in psychotherapy [41], although not 1:1. The 
nature of this trial was different in several aspects: (1) structuring treatment and continuing 
assessment was part of the intervention itself; (2) the trial – a non-medical intervention – was 
conducted in a population with multiple substance use disorder, where drop-out with low 
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adherence and attendance rates are common [42], and (3) the design provided the inclusion of 
experienced therapists themselves to realise the intervention. 
As a consequence, this study had limitations. Conducting a well-structured 
randomized controlled trial in a natural setting, where no manuals or protocols are used, does 
limit the conditions in the control group, because of  possible contamination [15] [14]. To 
keep the design pure, further structuring and assessments in the control group were not 
designated. Therefore, the primary outcome measure was limited to adherence at and beyond 
eight sessions and no other outcome measures were included. Studies in psychotherapy have 
found that 25% of patients reach clinically significant change in subjective discomfort, 
interpersonal relationships and social role functioning after five sessions, 50% reach clinically 
significant change after nine sessions, and 75% do so after 17 sessions [43]. In this study, 
most of the benefit was expected next to the first seven sessions, during which patients in the 
experiment were exposed to the assessment with feedback sessions. Application of a cut-point 
at twelve sessions also showed significant differences between the control group and the 
experimental group.  
The strengths of this trial included its being built upon an already existing monitoring 
system, the use of well evaluated instruments and that it is associated with the real-world 
context where the intervention took place. Other than establishing protocols and providing a 
manual and continued training and supervision, the researcher had no influence on common 
processes in each centre in terms of managing capacity limitations on the unpredictable 
behaviour of patients. In all likelihood, the realised randomization and the participation level 
in a natural setting was the highest that could be reached in a trial where the trial’s focus itself 
could lead to an increased workload without the benefit of additional clinical staff [40]. 
Moreover, the intervention took place within a real clinician-patient relationship, where good 
communication should consist of both instrumental (here, the trial intervention), and affective 
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behaviours. Both elements, although unfavourable to meeting the internal validity benchmark, 
certainly enhanced external validity, and thus contributed to contextual evidence, favouring 
the probability of adoption in clinical settings [44, 45]. The results may also have significance 
in the broader area of health care, where low compliance rates are of concern in case of 
preventive advice and/or chronic conditions to cope with. 
 
CONCLUSION  
The use of assessment instruments with feedback directly to patients provided 
evidence to enhance adherence in routine practice in the treatment of substance use disorder. 
This finding may inspire the broader field of health care, especially in the care of chronic 
conditions and mental health to further elaborate continued measurement and outcome-
feedback in daily practice. More research is needed to evaluate progress in social functioning 
and motivation to change in the treatment of substance use disorder, thereby using objective 
measures. 
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Figure: Flow-chart of patient-acceptance process for the trial
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Table 1: Scheduling of planned assessment and feedback sessions 
session 
number 
experimental group 
planned assessment and feedback 
control group 
1 information plus consent  
First Readiness to Change Questionnaire (RCQ)  
Regular session 
2 First RCQ (1) Regular session 
3 Feedback on first RCQ Regular session 
4 Regular session Regular session 
5 Personal Resources Diagnostic system (PREDI), part one Regular session 
6 PREDI, part two Regular session 
7 Feedback on PREDI Regular session 
8 Regular session Regular session 
9 Second RCQ (±30 days after first RCQ) Regular session 
10 Feedback on second RCQ Regular session 
11 Regular session Regular session 
12 … … 
(1) in some cases the First RCQ was completed at the same session where informed consent was given, in 
other cases at the next session 
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Table 2: Sample characteristics at baseline by allocation 
 
 Experimental 
(n=142) 
Control 
(n=138) 
Pearson Chi2 
or T-value 
p  
Mean age ±SD,y 27.4 ±7.1 26.9 ±6.6 .59 .55 n.s. 
Men, n (%) 120 (84.5) 108 (78.3) 1.8 .22 n.s. 
Country of birth, n (%)  
Belgium 
Other 
 
131 
11 
 
(92.3) 
(7.7) 
 
134 
4 
 
(97.1) 
(2.9) 
 
8.3 
 
.49 
 
n.s. 
Relationship, n (%) 
Never been Married  
Living situation, n(%) 
Partner & children 
Partner no children 
With parents 
Alone 
 
119 
 
19 
23 
45 
35 
 
(83.8) 
 
(13.4) 
(16.2) 
(31.7) 
(24.6) 
 
111 
 
18 
31 
37 
29 
 
(80.4) 
 
(13.0) 
(22.5) 
(26.8) 
(21.0) 
 
3.6 
 
9.6 
 
.61 
 
.30 
 
n.s. 
 
n.s. 
Educational level, n (%) 
<=vocational until 2nd degree 
Vocational & 3rd or 4th degree 
Technical secondary 
General Secondary 
 
58 
37 
24 
8 
 
(42.6) 
(26.1) 
(16.9) 
(5.6) 
 
56 
30 
20 
12 
 
(42.1) 
(21.7) 
(14.5) 
(8.7) 
 
7.2 
 
.62 
 
n.s. 
Employment status, n (%) 
Employed full-time or part-time 
Profession, n(%)  
Unschooled labour 
Schooled labour 
Other or missing 
 
94 
 
71 
41 
30 
 
(68.1) 
 
(50.0) 
(28.9) 
(21.1) 
 
90 
 
52 
45 
41 
 
(65.2) 
 
(37.7) 
(32.6) 
(29.7) 
 
8.8 
 
7.5 
 
.26 
 
.28 
 
n.s. 
 
n.s. 
Primary substance, n (%) 
Amphetamines 
Cannabis 
 
17 
38 
 
(12.0) 
(26.8) 
 
12 
51 
 
(8.7) 
(37.0) 
 
17.4 
 
.19 
 
n.s. 
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Cocaine 
Opiates 
30 
30 
(21.1) 
(21.1) 
19 
19 
(13.7) 
(13.8) 
Mean years of drug use  ±SD 
Amphetamines 
Cannabis 
Cocaine 
Opiates 
 
4.6 ±5.0 
8.0 ±5.8 
3.1 ±3.7 
3.8 ±4.1 
 
3.3 ±3.1 
7.9 ±5.4 
3.1 ±3.7 
3.0 ±2.3 
 
1.8 
.91 
-.10 
1.0 
 
.07 
.84 
.92 
.30 
 
n.s. 
n.s. 
n.s. 
n.s. 
Mean n of drugs ever used ±SD 3.9 ±2.0 3.7 ±1.9 .98 .38 n.s. 
Mean n of treatments drugs ±SD  1.0 ±1.3 0.9 ±1.3 .64 .52 n.s. 
EASI-severity >=4, n (%) 
Physical health 
Education, Work, Income 
Alcohol use 
Drug use 
Judicial 
Relations 
Psycho-emotional 
 
20 
38 
33 
135 
35 
78 
71 
 
(14.4) 
(28.0) 
(23.4) 
(89.5) 
(25.0) 
(56.5) 
(51.4) 
 
21 
45 
35 
122 
43 
72 
72 
 
(15.3) 
(33.9) 
(25.2) 
(88.4) 
(11.8) 
(52.5) 
(52.5) 
 
4.4 
17.0 
6.5 
10.6 
11.8 
6.6 
2.0 
 
.82 
.02 
.60 
.06 
.11 
.47 
.96 
 
n.s. 
<.05 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
Mean EASI Severity Indexes ±SD 
Physical health 
Education, Work, Income  
Alcohol 
Drugs 
Legal 
Family 
Psycho-emotional 
 
2.0 ±1.6 
2.5 ±1.5 
2.3 ±1.7 
5.0 ±1.1 
2.4 ±1.7 
3.8 ±1.5 
3.5 ±1.8 
 
1.9 ±1.6 
2.5 ±1.8 
2.2 ±1.9 
4.6 ±1.1 
2.4 ±2.0 
3.6 ±1.6 
3.4 ±1.9 
 
.34 
.13 
.47 
3.1 
-.09 
.85 
.76 
 
.73 
.90 
.64 
.002 
.93 
.40 
.90 
 
n.s. 
n.s. 
n.s. 
<.05 
n.s. 
n.s. 
n.s. 
EASI: EuropASI; n.s.: not significant; EASI-severity >=4 means that treatment is needed [46] 
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Table 3: Adherence at and beyond eight and twelve sessions in intention-to-treat and per-
protocol analysis 
 
 >= 8 sessions >= 12 sessions 
Intention-to-treat (n=227)   
experimental 53.4% 33.6% 
control 34.2% 20.7% 
Risk ratio (RR)  1.6 1.6 
95%CI 1.2-2.1 1.0-2.5 
Per-protocol (n=211)   
experimental 56.0% 36.0% 
control 34.2% 20.7% 
Risk ratio (RR) 1.6 1.7 
95%CI 1.2-2.2 1.1-2.7 
 
  
Randomized (n=280) 
Assessed for eligibility 
(n=320) 
Allocated to Treatment-as-usual 
(n=138) 
 
Received treatment-as-usual 
(n=111) 
Did not present anymore after 
allocation (n= 27) 
 
Allocated to Intervention (n=142) 
 
 
Received intervention (n=116) 
 
Did not present anymore after 
allocation(n=26) 
Excluded (n=40) 
Did not meet inclusion 
criteria:  
- EuropASI missing 
(n=4) 
- Language problem 
(n=2) 
- Group treatment a/o 
medical treatment 
(n=31) 
- Refused use of baseline 
data and follow-up 
contact (n=3) 
Start Treatment-as-usual (n=111) Start Intervention (n=116) 
- refused intervention (n=16) 
 
Analyzed (n=111) Analyzed (n=116) 
Analyzed (n=111) Analyzed (n=100) 
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